Reference:
Kory, P., Meduri, G. U., Varon, J., Iglesias, J., & Marik, P. E. (2021). Review of the emerging evidence demonstrating the efficacy of ivermectin in the prophylaxis and treatment of COVID-19. American Journal of Therapeutics, 28(3), e299–e318. https://doi.org/10.1097/MJT.0000000000001163
Summary:
This article reviews evidence supporting ivermectin as an effective treatment and prophylactic agent for COVID-19. Initially, various treatments were explored, but only corticosteroids showed confirmed benefits. Ivermectin, an antiparasitic drug, has displayed antiviral and anti-inflammatory properties. The review highlights numerous studies showing reduced mortality and hospitalisations in patients treated with ivermectin, alongside significant positive outcomes in prophylaxis trials, including decreased transmission rates. Meta-analyses indicate substantial efficacy in both treatment and prevention phases. The authors advocate for the global use of ivermectin, acknowledging its safety, low cost, and availability, despite some ongoing debates regarding its effectiveness in the broader scientific community.